ClinicalTrials.gg
CompletedNCT06535789INHALE-GDMUpdated Oct 19, 2026

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

A Phase 2/3 interventional study of Inhaled Technosphere Insulin in Diabetes, Gestational, Pregnancy Complications and Glucose Metabolism Disorders, sponsored by Jaeb Center for Health Research. Completed at 5 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Jaeb Center for Health Research · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.

Enrollment
142nd of 194
30 · median 80
Started
2025
with 24 others
Phase 2/3
2 of 251
1 open now
Registered
217th of 251
by date

Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 142nd largest by enrollment of the 194 interventional ones that give a count, is one of 25 that started in 2025, is one of 2 in phase 2/3, and was the 217th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Diabetes, Gestational with a site in United States, or all of them as a file.
02

Study summary

Pregnant women aged 18-45 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.

Read the detailed description

Gestational diabetes mellitus (GDM) affects up to 25% of births globally, and its rates continue to rise each year. Pregnancy is a dynamic time marked by rapid changes in physiology, anatomy, and metabolism that support the growth and development of the fetus. This period can also be vulnerable, as expectant mothers may experience shifts in body perception, food preferences, and physical fitness, which can lead to decreased self-esteem, depression, and anxiety. A diagnosis of GDM often catches women by surprise and may bring feelings of guilt and anxiety about the potential effects on their baby's health. For pregnant individuals unable to meet specific glucose targets through diet and exercise alone, insulin is recommended as the primary treatment. However, transitioning to insulin injections can provoke fear, stress, and discomfort-both emotionally and physically-for many patients. Consequently, some pregnant women opt for oral anti-diabetic medications like metformin or glyburide due to their apprehension about using insulin injections. Both of these drugs pass through the placenta and raise safety concerns, making them secondary choices according to the American Diabetes Association (ADA) and the American College of Obstetricians and Gynecologists (ACOG).

While GDM is typically managed with injectable insulin, inhalable insulin offers a potential alternative. Technosphere® Insulin inhalation powder (TI) is an ultra-rapid-acting insulin administered via oral inhalation using a breath-powered inhaler. It provides an alternative to injectable insulin for prandial glucose control. It consists of recombinant human insulin adsorbed onto fumaryl diketopiperazine (FDKP), a proprietary excipient that, at acidic pH, self-assembles into particles, and polysorbate 80. TI particles have a median diameter of approximately 2 to 2.5 μm, a size appropriate for inhalation into the lung. Following inhalation, Afrezza particles dissolve immediately at the physiologic pH of the lung, and insulin and FDKP are absorbed systemically. After administration of TI in adults, the maximum serum insulin concentration occurs in approximately 12 to 15 minutes (versus 45 to 60 minutes for RAA via subcutaneous route) and returns to near baseline levels in approximately 180 minutes (versus about 5 hours for RAA).

The United States Food and Drug Administration (FDA) approved TI Inhalation Powder and the Gen2 Inhaler (a dry powder device) as Afrezza® to improve blood sugar control in adults aged 18 years and older with diabetes on June 27, 2014. Inhaled TI has proven safe and effective in reducing postprandial (after-meal) hyperglycemia in individuals with Type 1 and Type 2 diabetes. It's important to note that TI units are not equivalent to injectable insulin units; TI's bioequivalent dose has been found to be about twice that of injectable rapid-acting insulin when prescribed for diabetes management.

All insulins, including TI, have a similar label wording with respect to use in pregnancy indicating that studies have not shown an association of insulin and birth defects and that there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy. Insulin, whether subcutaneously administered or inhaled, has not been demonstrated to cross the placenta secondary to its large molecular weight. TI's inert excipient FDKP is not metabolized and is fully excreted from the body with the majority in urine and some in the feces (i.e. for the amount swallowed). Animal studies using subcutaneous administration of carrier particles at 21 times human dosing demonstrated no adverse fertility, teratogenicity, or other developmental outcomes (described in Afrezza label).

TI's optimal dosing, efficacy and risk for hypoglycemia in pregnancy is unknown. Outside of pregnancy, TI has been shown to cause less hypoglycemia than RAA insulin. The dose conversions of TI from RAA therapy have not been characterized in pregnancy to effectively administer across gestation with the dynamic metabolic changes, although insulin resistance is high in the 3rd trimester and dosing is expected to be at least as high as in patients with T2D (\~2X SQ insulin dosing).

The goal of this investigator-initiated randomized crossover trial is to assess the efficacy of TI in lowering PP glycemia and the frequency of hypoglycemia compared with subcutaneous RAA insulin among pregnant individuals with GDM.

03

Conditions studied

  • Diabetes, Gestational
  • Pregnancy Complications
  • Glucose Metabolism Disorders
  • Glucose Intolerance During Pregnancy

Keywords

  • Gestational Diabetes
  • Inhaled Insulin
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide for study participation.
  2. Age ≥18 years and \<46 years old.
  3. Singleton pregnancy less than 34 weeks gestation.
  4. Diagnosis of GDM via standard 1-step or 2-step criteria OR evidence of hyperglycemia consistent with GDM per investigator judgment with subsequent treatment instituted.
  5. Treated with an insulin regimen that includes a RAA bolus of any type for breakfast, with a dose \<20 units.
  6. Pre-pregnancy or first trimester (BMI) 23-55.
  7. Investigator believes that the protocol can be safely conducted by the participant.
  8. Able to read and speak English or Spanish.

Exclusion criteria

Exclusion Criteria

  1. Preexisting (preconception) diagnosis of type 1 diabetes or type 2 diabetes and/or using insulin therapy at conception.
  2. ≥ 6.5%, fasting blood glucose (FBG) ≥125 mg/dL or 2-hr glucose ≥200 mg/dL on 75 g OGTT, or random plasma glucose ≥200 mg/dL (consistent with pre-existing diabetes and not GDM diagnosis)
  3. Current use of any non-insulin glucose lowering medication, other than metformin.
  4. Using TI (Afrezza), regular insulin, or ≥20 RAA units at breakfast (NPH is permissible)
  5. Peak expiratory flow \<80% predicted as measured by peak flow meter
  6. Recent history of asthma (defined as using any medications to treat asthma within the last year), (COPD), or any other pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator
  7. Smoking (includes cigarettes, cigars, pipes, and/or vaping devices) within 90 days prior to screening
  8. History or current diagnosis of lung cancer
  9. Current or anticipated use of oral, inhaled or injectable during the time period of the trial (topical glucocorticoid use is acceptable)
  10. Renal or hepatic impairment that in the investigator's judgment poses a safety risk for the study participant
  11. Recurrent Level 2 (blood glucose \<54 mg/dL) or Level 3 severe hypoglycemia events
  12. Current use of non-cardio-selective beta blockers
  13. Being a member of the study team, having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    technosphere insulin (TI)

    All participants will ingest one standardized meal using technosphere insulin to manage their blood glucose

    Drug: Inhaled Technosphere Insulin

  • No intervention
    Rapid-acting insulin analog

    All participants will ingest one standardized meal using their prescribed rapid-acting insulin analog (RAA) to manage their blood glucose

Interventions

  • DrugInhaled Technosphere Insulin

    Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal

06

What researchers measure

Primary outcomes

  1. Post-prandial AUC120

    3-hour post-prandial (PP) area under the curve \>120 mg/dL (AUC120)

    Time frame: 3 hours from start of meal

Secondary outcomes

  1. AUC >140 mg/dL

    AUC \>140 mg/dL over 3 hours PP

    Time frame: 3 hours from start of meal

  2. Excursion from baseline glucose to peak glucose

    Excursion from baseline blood glucose to peak blood glucose during 3 hours PP

    Time frame: 3 hours from start of meal

  3. Maximum peak glucose

    Maximum peak blood glucose during 3 hours PP

    Time frame: 3 hours from start of meal

  4. Time to peak glucose

    Time to peak blood glucose during 3 hours PP

    Time frame: 3 hours from start of meal

  5. Nadir glucose

    Nadir (lowest) blood glucose during 3 hours PP

    Time frame: 3 hours from start of meal

  6. Mean CGM glucose

    Mean CGM glucose during 3 hours PP

    Time frame: 3 hours from start of meal

  7. Time with glucose >120 mg/dL

    Time with blood glucose \>120 mg/dL during 3 hours PP

    Time frame: 3 hours from start of meal

  8. Time with glucose >140 mg/dL

    Time with blood glucose \>140 mg/dL during 3 hours PP

    Time frame: 3 hours from start of meal

  9. Glucose ≤140 mg/dL

    Blood Glucose ≤140 mg/dL at 1 hour PP

    Time frame: 1 hour from start of meal

  10. Glucose ≤140 mg/dL

    Blood Glucose ≤140 mg/dL at 2 hours PP

    Time frame: 2 hours from start of meal

  11. Glucose ≤140 mg/dL

    Blood Glucose ≤140 mg/dL at 3 hours PP

    Time frame: 3 hours from start of meal

  12. Glucose ≤120 mg/dL

    Blood Glucose ≤120 mg/dL at 1 hour PP

    Time frame: 1 hour from start of meal

  13. Glucose ≤120 mg/dL

    Blood Glucose ≤120 mg/dL at 2 hours PP

    Time frame: 2 hours from start of meal

  14. Glucose ≤120 mg/dL

    Blood Glucose ≤120 mg/dL at 3 hours PP

    Time frame: 3 hours from start of meal

  15. Time with Glucose in range 63-120 mg/dL

    Time with Blood Glucose in range 63-120 mg/dL during 3 hours PP

    Time frame: 3 hours from start of meal

  16. Time with Glucose in range 63-140 mg/dL

    Time with Blood Glucose in range 63-140 mg/dL during 3 hours PP

    Time frame: 3 hours from start of meal

Other outcomes

  1. Any blood glucose <54 mg/dL

    Any blood glucose \<54 mg/dL during 3 hours PP

    Time frame: 3 hours from start of meal

  2. Any blood glucose <63 mg/dL

    Any blood glucose \<63 mg/dL during 3 hours PP

    Time frame: 3 hours from start of meal

  3. Any blood glucose <70 mg/dL

    Any blood glucose \<70 mg/dL during 3 hours PP

    Time frame: 3 hours from start of meal

  4. Percent time glucose <63 mg/dL

    CGM time with glucose \<63 mg/dL during 3 hours PP

    Time frame: 3 hours from start of meal

  5. Hypersensitivity to inhaled technosphere insulin

    Hypersensitivity reaction, acute bronchospasm, treatment provided for asthma symptoms, or other symptoms associated with TI dosing

    Time frame: From the time of administration of the first Technosphere Insulin (TI) dose during the meal session until the end of the calendar day (11:59 PM) on the day of the TI meal session, assessed for up to 18 hours.

  6. Severe Hypoglycemia events during the clinic meal session

    Any severe hypoglycemia events during the clinic meal session, defined as events requiring assistance of another person due to cognitive impairment to actively administer carbohydrate, glucagon, or other resuscitative actions

    Time frame: From the time of administration of insulin (either Technosphere Insulin [TI] or RAA, depending on the meal session visit) until discharge from the clinic, assessed up to 5 hours for each meal session.

  7. Severe hypoglycemia events during the study period

    Any severe hypoglycemia events during the study period (defined as the time between screening and the final study visit)

    Time frame: From Screening to Study Completion, an average of 10 days

07

Study locations

5 sites
  • Sansum Diabetes Research Institute
    Santa Barbara, California 93105, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2025 to primary completion in Sep 2026, 15 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start May 2025 → Jun 2025, primary completion Jul 2025 → Sep 2026 and completion Jul 2025 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 2, 2024
StartActual
Jun 2, 2025was May 2025
Primary completionActual
Sep 5, 2026was Jul 2025
CompletionActual
Sep 5, 2026was Jul 2025
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Sites
1 site added, 1 site removed
Show site
  • Icahn School of Medicine at Mount Sinai · New York, United States
Show 1 removed
  • Icahn School of Medicine at Mount Sinai · New York City, United States
Oct 19, 2026
Start date
May 2025→Jun 2, 2025 (actual)
Oct 19, 2026
Primary completion
Jul 2025→Sep 5, 2026 (actual)
Oct 19, 2026
Study completion
Jul 2025→Sep 5, 2026 (actual)
Oct 19, 2026
Eligibility
Maximum age 40 Years→45 Years; 5 inclusion criteria edited; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAge ≥18 years and <4146 years old.
  • EditedSingleton pregnancy at 24-less than 34 weeks gestation.
  • EditedDiagnosis of GDM via standard 1-step or 2-step criteria OR evidence of hyperglycemia consistent with GDM per investigator judgment with subsequent treatment instituted.
  • EditedPre-pregnancy or first trimester body mass index (BMI) 2523-4555.
  • EditedAble to read and speak English or Spanish.
Exclusion criteria
  • ChangedBefore Type 1 diabetes or type 2 diabetesNow Preexisting (preconception) diagnosis of type 1 diabetes or type 2 diabetes and/or using insulin therapy at conception.
  • EditedHbA1c ≥ 6.5%, fasting blood glucose (FBG) ≥125 mg/dldL or 2-hr glucose ≥200 mg/dL on 75g75 g OGTT, or random plasma glucose ≥200 mg/dL (consistent with pre-existing diabetes and not GDM diagnosis)
  • EditedCurrent use of any non-insulin glucose lowering medication, other than metformin.
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Icahn School of Medicine at Mount Sinai · New York, United States
    Show 1 removed
    • Icahn School of Medicine at Mount Sinai · New York City, United States
    Start date May 2025→Jun 2, 2025 (now actual)
    Primary completion Jul 2025→Sep 5, 2026 (now actual)
    Study completion Jul 2025→Sep 5, 2026 (now actual)
    Eligibility Maximum age 40 Years→45 Years; 5 inclusion criteria edited; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAge ≥18 years and <4146 years old.
    • EditedSingleton pregnancy at 24-less than 34 weeks gestation.
    • EditedDiagnosis of GDM via standard 1-step or 2-step criteria OR evidence of hyperglycemia consistent with GDM per investigator judgment with subsequent treatment instituted.
    • EditedPre-pregnancy or first trimester body mass index (BMI) 2523-4555.
    • EditedAble to read and speak English or Spanish.
    Exclusion criteria
    • ChangedBefore Type 1 diabetes or type 2 diabetesNow Preexisting (preconception) diagnosis of type 1 diabetes or type 2 diabetes and/or using insulin therapy at conception.
    • EditedHbA1c ≥ 6.5%, fasting blood glucose (FBG) ≥125 mg/dldL or 2-hr glucose ≥200 mg/dL on 75g75 g OGTT, or random plasma glucose ≥200 mg/dL (consistent with pre-existing diabetes and not GDM diagnosis)
    • EditedCurrent use of any non-insulin glucose lowering medication, other than metformin.
    + 6 other changes: verification date, registry dates, description, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06535789
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
Jun 2, 2025
Primary completion
Sep 5, 2026
Completion
Sep 5, 2026
Last update
Oct 19, 2026

Study contacts

Amy Valent, DO
study chair · Oregon Health and Science University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion